PRMT5 is a therapeutic target in choroidal neovascularization
A. Muniyandi, M. Martin, M. Sun, K. Sishtla, N. R. Jensen, A. Motolani, X. Qi, M. E. Boulton, L. Prabhu, T. Lu, T. W. Corson
This study identifies PRMT5 as a therapeutic target for neovascular age-related macular degeneration by showing its inhibition reduces NF-κB activity and angiogenic properties in ocular endothelial cells.
bioRxiv · Mar 30, 2022Pharmacology & Toxicology